Technology ID
TAB-2694
Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics
E-Numbers
E-210-2013-0
Lead Inventor
Goldstein, Jason
Lead IC
CDC
Co-Inventors
Bagarozzi, Dennis
Boyer, Anne
Quinn, Conrad
ICs
CDC
Applications
Vaccines
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Pre-Clinical (in vitro)
Development Status
- Early-stage
- In vitro data available
Research Products
Research Equipment
Antibodies
CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax vaccine.
Commercial Applications
- Diagnostic tests assessing active Lethal Factor in a sample
- Anthrax neutralizing therapeutics and vaccines for B. anthracis
- Biodefense, biosecurity
Competitive Advantages
- Potentially faster, lower-input assay compared to current Edema Factor detection methods
- Easily adaptable for high-throughput screening of numerous specimens
Licensing Contact: